Advertisement

Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation

Published:October 16, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.09.046
      Novel oral anticoagulants (NOACs) are safe and effective for the prevention of stroke or systemic embolism (S/SE) in atrial fibrillation. The efficacy and safety of NOACs compared with warfarin has not been systematically assessed in subjects with mild or moderate renal dysfunction. We performed a meta-analysis of the randomized clinical trials that compared efficacy and safety (major bleeding) outcomes of NOACs compared to warfarin for the treatment of nonvalvular atrial fibrillation and had available data on renal function. We estimated the pooled relative risk (RR) of S/SE and major bleeding in relation to renal function (assessed by baseline estimated glomerular filtration rate divided in 3 groups: normal [estimated glomerular filtration rate >80 ml/min], mildly impaired [50 to 80 ml/min], and moderate impairment [<50 ml/min]). We included 4 randomized clinical trials enrolling a total of 58,338 subjects. The RRs of S/SE and major bleeding were higher in subjects with renal impairment compared to normal renal function, independent of type of anticoagulant therapy. In subjects with normal renal function, no difference in the risk of S/SE was observed, whereas the risk of major bleeding was slightly lower for subjects taking NOACs (RR 0.87, 95% confidence interval [CI] 0.76 to 0.99). In subjects with mild or moderate renal impairment, NOACs were associated with a reduced risk of S/SE (RR 0.75, 95% CI 0.66to 0.85 and RR 0.80, 95% CI 0.68 to 0.94, respectively) and major bleeding (RR 0.87, 95% CI 0.79 to 0.95 and RR 0.80, 95% CI 0.71 to 0.91, respectively) compared to warfarin. The pooled analysis for major bleeding demonstrated significant heterogeneity. In conclusion, the use of NOACs was associated with a reduced risk of S/SE and reduced risk of major bleeding compared to warfarin in subjects with mild or moderate renal impairment suggesting a favorable risk profile of these agents in patients with renal disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Go A.S.
        • Hylek E.M.
        • Chang Y.
        • Phillips K.A.
        • Henault L.E.
        • Capra A.M.
        • Jensvold N.G.
        • Selby J.V.
        • Singer D.E.
        Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?.
        JAMA. 2003; 290: 2685-2692
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • Eikelboom J.
        • Oldgren J.
        • Parekh A.
        • Pogue J.
        • Reilly P.A.
        • Themeles E.
        • Varrone J.
        • Wang S.
        • Alings M.
        • Xavier D.
        • Zhu J.
        • Diaz R.
        • Lewis B.S.
        • Darius H.
        • Diener H.C.
        • Joyner C.D.
        • Wallentin L.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Patel M.R.
        • Mahaffey K.W.
        • Garg J.
        • Pan G.H.
        • Singer D.E.
        • Hacke W.
        • Breithardt G.
        • Halperin J.L.
        • Hankey G.J.
        • Piccini J.P.
        • Becker R.C.
        • Nessel C.C.
        • Paolini J.F.
        • Berkowitz S.D.
        • Fox K.A.
        • Califf R.M.
        • ROCKET AF Investigators
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • Lopes R.D.
        • Hylek E.M.
        • Hanna M.
        • Al-Khalidi H.R.
        • Ansell J.
        • Atar D.
        • Avezum A.
        • Bahit M.C.
        • Diaz R.
        • Easton J.D.
        • Ezekowitz J.A.
        • Flaker G.
        • Garcia D.
        • Geraldes M.
        • Gersh B.J.
        • Golitsyn S.
        • Goto S.
        • Hermosillo A.G.
        • Hohnloser S.H.
        • Horowitz J.
        • Mohan P.
        • Jansky P.
        • Lewis B.S.
        • Lopez-Sendon J.L.
        • Pais P.
        • Parkhomenko A.
        • Verheugt F.W.
        • Zhu J.
        • Wallentin L.
        • ARISTOTLE Committees and Investigators
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Giugliano R.P.
        • Ruff C.T.
        • Braunwald E.
        • Murphy S.A.
        • Wiviott S.D.
        • Halperin J.L.
        • Waldo A.L.
        • Ezekowitz M.D.
        • Weitz J.I.
        • Spinar J.
        • Ruzyllo W.
        • Ruda M.
        • Koretsune Y.
        • Betcher J.
        • Shi M.G.
        • Grip L.T.
        • Patel S.P.
        • Patel I.
        • Hanyok J.J.
        • Mercuri M.
        • Antman E.M.
        • ENGAGE AF-TIMI 48 Investigators
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Tahir F.
        • Riaz H.
        • Riaz T.
        • Badshah M.B.
        • Riaz I.B.
        • Hamza A.
        • Mohiuddin H.
        The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature.
        Thromb J. 2013; 11: 18
        • Hart R.G.
        • Eikelboom J.W.
        • Brimble K.S.
        • McMurtry M.S.
        • Ingram A.J.
        Stroke prevention in atrial fibrillation patients with chronic kidney disease.
        Can J Cardiol. 2013; 29: S71-S78
        • Hart R.G.
        • Eikelboom J.W.
        • Ingram A.J.
        • Herzog C.A.
        Anticoagulants in atrial fibrillation patients with chronic kidney disease.
        Nat Rev Nephrol. 2012; 8: 569-578
        • Mao L.
        • Li C.
        • Li T.
        • Yuan K.
        Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation.
        Vascular. 2014; 22: 252-258
        • Connolly S.J.
        • Eikelboom J.
        • Joyner C.
        • Diener H.C.
        • Hart R.
        • Golitsyn S.
        • Flaker G.
        • Avezum A.
        • Hohnloser S.H.
        • Diaz R.
        • Talajic M.
        • Zhu J.
        • Pais P.
        • Budaj A.
        • Parkhomenko A.
        • Jansky P.
        • Commerford P.
        • Tan R.S.
        • Sim K.H.
        • Lewis B.S.
        • Van Mieghem W.
        • Lip G.Y.
        • Kim J.H.
        • Lanas-Zanetti F.
        • Gonzalez-Hermosillo A.
        • Dans A.L.
        • Munawar M.
        • O'Donnell M.
        • Lawrence J.
        • Lewis G.
        • Afzal R.
        • Yusuf S.
        Apixaban in patients with atrial fibrillation.
        N Engl J Med. 2011; 364: 806-817
        • Ezekowitz M.D.
        • Reilly P.A.
        • Nehmiz G.
        • Simmers T.A.
        • Nagarakanti R.
        • Parcham-Azad K.
        • Pedersen K.E.
        • Lionetti D.A.
        • Stangier J.
        • Wallentin L.
        Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
        Am J Cardiol. 2007; 100: 1419-1426
        • Chung N.
        • Jeon H.K.
        • Lien L.M.
        • Lai W.T.
        • Tses H.F.
        • Chung W.S.
        • Lee T.H.
        • Chen S.A.
        Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
        Thromb Haemost. 2011; 105: 535-544
        • Connolly S.J.
        • Eikelboom J.
        • Dorian P.
        • Hohnloser S.H.
        • Gretler D.D.
        • Sinha U.
        • Ezekowitz M.D.
        Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa).
        Eur Heart J. 2013; 34: 1498-1505
        • Lip G.Y.
        • Rasmussen L.H.
        • Olsson S.B.
        • Zetterstrand S.
        • Stahre C.
        • Bylock A.
        • Aunes-Jansson M.
        • Eriksson U.
        • Wahlander K.
        • Steering C.
        Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy.
        Thromb Res. 2011; 127: 91-99
        • Ogawa S.
        • Shinohara Y.
        • Kanmuri K.
        Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study.
        Circ J. 2011; 75: 1852-1859
        • Weitz J.I.
        • Connolly S.J.
        • Patel L.
        • Salazar D.
        • Rohatagi S.
        • Mendell J.
        • Kastrissioss H.
        • Lin J.Q.
        • Kunitada S.
        Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
        Thromb Haemost. 2010; 104: 633-641
        • Yamashita T.
        • Koretsune Y.
        • Yasaka M.
        • Inoue H.
        • Kawai Y.
        • Yamaguchi T.
        • Uchiyama S.
        • Matsumoto M.
        • Ogawa S.
        Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation.
        Circ J. 2012; 76: 1840-1847
        • Fox K.A.
        • Piccini J.P.
        • Wojdyla D.
        • Becker R.C.
        • Halperin J.L.
        • Nessel C.C.
        • Paolini J.F.
        • Hankey G.J.
        • Mahaffey K.W.
        • Patel M.R.
        • Singer D.E.
        • Califf R.M.
        Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
        Eur Heart J. 2011; 32: 2387-2394
        • Hijazi Z.
        • Hohnloser S.H.
        • Oldgren J.
        • Andersson U.
        • Connolly S.J.
        • Eikelboom J.W.
        • Ezekowitz M.D.
        • Reilly P.A.
        • Siegbahn A.
        • Yusuf S.
        • Wallentin L.
        Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY trial analysis.
        Circulation. 2014; 129: 961-970
        • Hohnloser S.H.
        • Hijazi Z.
        • Thomas L.
        • Alexander J.H.
        • Amerena J.
        • Hanna M.
        • Keltai M.
        • Lanas F.
        • Lopes R.D.
        • Lopez-Sendon J.
        • Granger C.B.
        • Wallentin L.
        Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.
        Eur Heart J. 2012; 33: 2821-2830
      1. Dabigatran Medical Review Application Number: 22–512. FDA Center for Drug Evaluation and Research, 2010 (Available at:)
      2. Rivaroxaban Medical Review Application Number: 202439. FDA Center for Drug Evaluation and Research, 2011 (Available at:)
      3. Apixaban Medical Review Application Number: 202155. FDA Center for Drug Evaluation and Research, 2012 (Available at:)
      4. Edoxaban Medical Review Application Number: 206316. FDA Center for Drug Evaluation and Research, 2015 (Available at:)
        • Banerjee A.
        • Fauchier L.
        • Vourc'h P.
        • Andres C.R.
        • Taillandier S.
        • Halimi J.M.
        • Lip G.Y.
        Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
        J Am Coll Cardiol. 2013; 61: 2079-2087
        • Roldan V.
        • Marin F.
        • Fernandez H.
        • Manzano-Fernandez S.
        • Gallego P.
        • Valdes M.
        • Vicente V.
        • Lip G.Y.
        Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding).
        Am J Cardiol. 2013; 111: 1159-1164
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • de Vos C.B.
        • Crijns H.J.
        • Lip G.Y.
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • Gage B.F.
        • Yan Y.
        • Milligan P.E.
        • Waterman A.D.
        • Culverhouse R.
        • Rich M.W.
        • Radford M.J.
        Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).
        Am Heart J. 2006; 151: 713-719